Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Agamree vs Duvyzat: how two US-approved medicines for Duchenne muscular dystrophy compare

Creator: Reserve Meds
Published: 2026-10-17

A side-by-side guide for families in the Gulf, built from the US FDA labels, Gulf drug registers and official sources.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Facts on this page come from the current US prescribing information for each medicine.

Agamree vs Duvyzat: the short answer

Agamree and Duvyzat are both US FDA-approved for Duchenne muscular dystrophy, but for different patients and in different ways. No trial has compared them head to head. Your specialist decides which, if either, fits. Reserve Meds is a digital health company. We do not diagnose or prescribe.

Condition: Duchenne muscular dystrophy.
Main difference: Both are taken by mouth as a liquid, but they are different kinds of medicine.
Head-to-head evidence: none in either US label.
Price: Quote on request.

Agamree and Duvyzat side by side

The table summarizes each current US label. Labels are long; your specialist and hospital pharmacy work from the full text.

Feature	Agamree	Duvyzat
Generic name	vamorolone^[2]	givinostat^[3]
Type of medicine	corticosteroid taken by mouth^[2]	histone deacetylase (HDAC) inhibitor taken by mouth^[3]
US-approved for	Duchenne muscular dystrophy in patients 2 years of age and older.^[2]	Duchenne muscular dystrophy in patients 6 years of age and older.^[3]
First US approval (year on the label)	2023^[2]	2024^[3]
How it is given	Oral suspension (40 mg/mL). The recommended dose is 6 mg/kg once daily, preferably with a meal, up to 300 mg a day for patients over 50 kg. Some patients may respond to 2 mg/kg a day.^[2]	Oral suspension (8.86 mg/mL) taken twice daily with food. The dose depends on body weight.^[3]
Where and what to expect	Taken at home. Immunizations should be given before starting, and live vaccines at least 4 to 6 weeks before. The dose is reduced gradually when stopping after more than one week.^[2]	Taken at home. Platelet counts and triglycerides are checked before starting and during treatment, and it is not started if the platelet count is below 150 x 10^9/L.^[3]
Boxed warning	No boxed warning. Warnings follow the corticosteroid class: hormone (adrenal) suppression, infections, blood pressure and salt changes, mood changes, bone and eye effects.^[2]	No boxed warning. Warnings: low platelets and other blood count changes, raised triglycerides, diarrhea and other stomach effects, and QTc prolongation.^[3]

About Duchenne muscular dystrophy and these two medicines

Duchenne muscular dystrophy is a genetic condition that causes progressive muscle weakness and wasting and affects heart muscle. It occurs almost exclusively in males. In boys with Duchenne, muscle weakness tends to appear in early childhood and worsen rapidly.^[1]

It is caused by mutations in the DMD gene, which provides instructions for making a protein called dystrophin. Muscle cells without enough dystrophin become damaged as muscles repeatedly contract and relax, and the damaged fibers weaken and die over time.^[1]

The main difference

Both are taken by mouth as a liquid, but they are different kinds of medicine. Agamree is a corticosteroid approved from age 2. Duvyzat is an HDAC inhibitor approved from age 6, taken twice daily with food, with platelet and triglyceride checks.^{[2, 3]}

The evidence behind each approval

Agamree. Study 1 (NCT03439670) was a 24-week randomized, double-blind study in 121 boys aged 4 to under 7 who had not taken corticosteroids. It compared Agamree 6 and 2 mg/kg a day with prednisone and with placebo. The primary endpoint (time to stand velocity, Agamree 6 mg/kg versus placebo) was met.^[2]

Duvyzat. Study 1 (NCT02851797) was an 18-month randomized, double-blind, placebo-controlled study in 179 ambulatory boys aged 6 and older who were on a stable dose of corticosteroids. Patients on Duvyzat showed statistically significant less decline in the 4-stair climb than placebo.^[3]

No head-to-head trial. Neither US label reports a study that compared Agamree directly with Duvyzat. The trials above enrolled different patients at different stages, so their results cannot be set side by side to decide which medicine works better.

Using one after the other

In the Duvyzat trial, every patient was already on a stable dose of corticosteroids, so Duvyzat was studied added to steroid treatment. Neither label reports a study of Duvyzat with Agamree specifically. Your specialist decides how they fit together.^{[2, 3]}

Safety: what the labels warn about

Both labels list warnings that the treating team monitors. The boxed warning row in the table above is the most serious level of warning on a US label.

Agamree: common side effects listed on the label include cushingoid features, psychiatric disorders, vomiting, weight gain and vitamin D deficiency.^[2]
Duvyzat: common side effects listed on the label include diarrhea, abdominal pain, low platelets, nausea or vomiting, raised triglycerides and fever.^[3]

Availability in the Gulf

Agamree: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Egypt
Duvyzat: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain

How families in the Gulf can access Agamree or Duvyzat

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks it, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[6, 7]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only and we do not choose between medicines.

Ask us about Agamree or Duvyzat

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Which is better, Agamree or Duvyzat?

There is no head-to-head trial, so no one can say from the evidence that one is better. They are approved for different patients and are given differently. Your specialist decides which fits, based on prior treatment, test results and overall health.

What is the main difference between Agamree and Duvyzat?

Are Agamree and Duvyzat available in Saudi Arabia or the UAE?

Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list.

How can a family in the Gulf get Agamree or Duvyzat?

Ask the treating hospital about local supply first. If the medicine is not registered, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much do these medicines cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds choose the medicine?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or choose between medicines. Your specialist and hospital make the medical decisions.

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.